Verastem's VS-7375 Shows Strong Anti-Tumor Activity in KRAS G12D Cancers

  • Verastem Oncology's VS-7375 demonstrated a 50% confirmed ORR in second-line pancreatic ductal adenocarcinoma and two complete responses in later-line disease.
  • The 900 mg QD dose of VS-7375 showed deeper tumor reductions and higher response rates compared to the 600 mg dose.
  • Verastem plans to open a Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma by year-end 2026.
  • The company reported favorable safety and tolerability profiles for VS-7375, with a low discontinuation rate due to adverse events.

Verastem Oncology's positive clinical data for VS-7375 underscores the growing focus on targeted therapies for KRAS G12D-mutant cancers, a segment with significant unmet medical needs. The robust anti-tumor activity and favorable safety profile position VS-7375 as a potential best-in-class therapy, potentially reshaping treatment paradigms for pancreatic, colorectal, and lung cancers. The strategic alignment with the FDA on Phase 3 trial designs further highlights the company's aggressive push to bring this novel therapy to market.

Clinical Efficacy
How the confirmed ORR and complete responses in KRAS G12D-mutant cancers will position VS-7375 against existing therapies.
Regulatory Pathway
Whether the FDA alignment on Phase 3 study design will accelerate approval timelines for VS-7375.
Combination Therapy
The pace at which Verastem can demonstrate the efficacy of VS-7375 in combination regimens across different tumor types.